Tilray Brands (TLRY) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- —
- Surprise
- —
- Score today
- 6.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Earnings Scheduled For October 8, 2026 — benzinga, 2026-10-08
- Tilray Brands Q1 Adj. EPS $(0.02) Beats $(0.20) Estimate, Sales $257.147M Miss $267.813M Estimate — benzinga, 2026-10-08
- Tilray Brands Q1 Adj. EPS $(0.02) Beats $(0.20) Estimate, Sales $257.147M Miss $267.464M Estimate — benzinga, 2026-10-08
Where TrendMatrix's rating stands now
TrendMatrix currently rates TLRY Sell at 6.0/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate.
What argues against it
- Quality below floor (2.3 < 4.0)
- Momentum score 4.3/10 — below 4.5 minimum
- Death cross — 50-day MA below 200-day MA
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.71
- Price target
- $6.23
- Stop
- $3.45
- Upside to target
- +67.7%
- Reward-to-risk
- 8.6:1
Model outputs from TrendMatrix’s engine as of 2026-10-08 — shown for context, not personalized investment advice.
TLRY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $549.0M
- P/E (fwd)
- 20.9
- 52-week range
- $3.54–$23.20
- Off 52-week high
- 84.0%
- RSI (14)
- 42
- Volume vs avg
- 0.83×
- Score today
- 6.0/10